adjuvant

(redirected from Adjuvant treatment)
Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to Adjuvant treatment: palliative treatment

adjuvant

 [aj´ah-vant, ă-joo´vant]
1. assisting or aiding.
2. a substance that aids another, such as an auxiliary remedy.

ad·ju·vant

(ad'jū-vănt),
1. A substance added to a drug product formulation that affects the action of the active ingredient in a predictable way.
2. immunology a vehicle used to enhance antigenicity; for example, a suspension of minerals (alum, aluminum hydroxide, or phosphate) on which antigen is adsorbed; or water-in-oil emulsion in which antigen solution is emulsified in mineral oil (Freund incomplete adjuvant), sometimes with the inclusion of killed mycobacteria (Freund complete adjuvant) to enhance antigenicity further (inhibits degradation of antigen and/or causes influx of macrophages).
3. Additional therapy given to enhance or extend primary therapy's effect, as in chemotherapy's addition to a surgical regimen.
4. A treatment added to a curative treatment to prevent recurrence of clinical cancer from microscopic residual disease.
[L. ad-juvo, pres. p. -juvans, to give aid to]

adjuvant

(ăj′ə-vənt)
n.
1. A treatment that enhances an existing medical regimen, as a pharmacological agent added to a drug to increase or aid its effect.
2. An immunological agent that increases the antigenic response.
adj.
Contributing to or enhancing an existing medical regimen: adjuvant chemotherapy

Adjuvant

Referring to a management strategy used in addition to the primary therapy.
Immunology A substance that enhances or diversifies the immune response; a nonspecific immune enhancer—e.g., Freund’s adjuvant, BCG vaccine—consisting of particulate-rich oily substances which promotes protein aggregation; adjuvant mixed with an antigen acts as a tissue depot, slowly releasing antigen and activating the immune system.
Pharmacology A drug that modulates the actions of other drugs which, when added to a medication, enhances its pharmacologic effect. See Interference.

adjuvant

Immunology Any nonspecific immune enhancer–eg Freund's adjuvant, BCG vaccine, consisting of a particulate-rich oily substances, which promotes protein aggregation; adjuvant mixed with an antigen acts as a tissue depot, slowly releasing antigen and activating the immune system Oncology The addition of chemotherapy to a traditional therapeutic modality to ↓ M&M Pharmacology A substance which, when added to a medication, enhances its pharmacologic effect. See Neoadjutant.

ad·ju·vant

(ad'jū-vănt)
1. A substance added to a drug product formulation that affects the action of the active ingredient in a predictable way.
2. immunology A vehicle used to enhance antigenicity.
3. Additional therapy given to enhance or extend primary therapy's effect, such as in chemotherapy in addition to a surgical regimen.
4. A treatment added to a curative treatment to prevent recurrence of clinical cancer from microscopic residual disease.
[L. ad-juvo, pres. p. -juvans, to give aid to]

adjuvant

1. Any substance added to a drug to increase its effect.
2. Any substance which, added to an ANTIGEN, non-specifically increases its power to stimulate the production of antibodies (see ANTIBODY).

adjuvant

a substance added to enhance a physical or chemical property, e.g. adjuvants are commonly added to ANTIGENS, improving the IMMUNE RESPONSE in the recipient and thus increasing the production of ANTIBODIES.

ad·ju·vant

(ad'jū-vănt)
1. Substance added to a drug product formulation that affects action of the active ingredient in a predictable way.
2. Additional therapy given to enhance or extend primary therapy's effect, as in chemotherapy's addition to a surgical regimen.
[L. ad-juvo, pres. p. -juvans, to give aid to]
References in periodicals archive ?
This US FDA approval of Sutent for the adjuvant treatment of renal cell carcinoma was based on the company's randomized trial of 615 patients with high risk of recurrent renal cell carcinoma following nephrectomy.
- Health Canada has accepted for review US-based biopharmaceutical company Puma biotechnology, Inc.'s (NASDAQ: PBYI) New Drug Submission for the medicinal product Nerlynx (neratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy, the company said.
Pfizer announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended against expanding use of SUTENT to include the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma following nephrectomy.
According to the companies, NERLYNX, which is a kinase inhibitor approved by the US Food and Drug Administration (FDA), is indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.
- New York, New York-based biopharmaceutical company Bristol-Myers Squibb (NYSE: BMY) has received a recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for expanded approval of the current indications for Opdivo (nivolumab) to include the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, the company said.
In the second-line setting, Keytruda is now approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
M2 PHARMA-July 6, 2018-European Regulatory Agency Recommends Nerlynx as Adjuvant Treatment for Certain HER-2 Breast Cancer Patients
Puma Biotechnology announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has communicated a negative trend vote after meeting with the company today to discuss the Marketing Authorisation Application for neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer.
BAVENCIO (avelumab) is a human programmed death ligand-1 (PD-L1) blocking antibody indicated in the US for locally advanced or metastatic urothelial carcinoma who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, concluded the companies.
Food and Drug Administration has approved Opdivo injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
The product is to be used for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab (Herceptin)-based therapy.
Neratinib (also called Nerlynx and marketed by Pierre Fabre) is recommended, under the terms of a commercial arrangement, for people with this type of breast cancer who are less than 1 year from completing trastuzumab (Herceptin)-based treatment following surgery (called adjuvant treatment).